Professional paper
Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma
Smiljka Popović-Suić
Borna Šarićić
Full text: croatian pdf 332 Kb
page 66-66
downloads: 567
cite
APA 6th Edition
Popović-Suić, S. & Šarićić, B. (2008). Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma. Acta clinica Croatica, 47 (Supplement 1), 63-66. Retrieved from https://hrcak.srce.hr/index.php/22769
MLA 8th Edition
Popović-Suić, Smiljka and Borna Šarićić. "Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma." Acta clinica Croatica, vol. 47, no. Supplement 1, 2008, pp. 63-66. https://hrcak.srce.hr/index.php/22769. Accessed 5 Jan. 2025.
Chicago 17th Edition
Popović-Suić, Smiljka and Borna Šarićić. "Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma." Acta clinica Croatica 47, no. Supplement 1 (2008): 63-66. https://hrcak.srce.hr/index.php/22769
Harvard
Popović-Suić, S., and Šarićić, B. (2008). 'Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma', Acta clinica Croatica, 47(Supplement 1), pp. 63-66. Available at: https://hrcak.srce.hr/index.php/22769 (Accessed 05 January 2025)
Vancouver
Popović-Suić S, Šarićić B. Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma. Acta clinica Croatica [Internet]. 2008 [cited 2025 January 05];47(Supplement 1):63-66. Available from: https://hrcak.srce.hr/index.php/22769
IEEE
S. Popović-Suić and B. Šarićić, "Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma", Acta clinica Croatica, vol.47, no. Supplement 1, pp. 63-66, 2008. [Online]. Available: https://hrcak.srce.hr/index.php/22769. [Accessed: 05 January 2025]
Full text: english pdf 332 Kb
page 63-66
downloads: 435
cite
APA 6th Edition
Popović-Suić, S. & Šarićić, B. (2008). Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma. Acta clinica Croatica, 47 (Supplement 1), 63-66. Retrieved from https://hrcak.srce.hr/index.php/22769
MLA 8th Edition
Popović-Suić, Smiljka and Borna Šarićić. "Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma." Acta clinica Croatica, vol. 47, no. Supplement 1, 2008, pp. 63-66. https://hrcak.srce.hr/index.php/22769. Accessed 5 Jan. 2025.
Chicago 17th Edition
Popović-Suić, Smiljka and Borna Šarićić. "Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma." Acta clinica Croatica 47, no. Supplement 1 (2008): 63-66. https://hrcak.srce.hr/index.php/22769
Harvard
Popović-Suić, S., and Šarićić, B. (2008). 'Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma', Acta clinica Croatica, 47(Supplement 1), pp. 63-66. Available at: https://hrcak.srce.hr/index.php/22769 (Accessed 05 January 2025)
Vancouver
Popović-Suić S, Šarićić B. Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma. Acta clinica Croatica [Internet]. 2008 [cited 2025 January 05];47(Supplement 1):63-66. Available from: https://hrcak.srce.hr/index.php/22769
IEEE
S. Popović-Suić and B. Šarićić, "Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma", Acta clinica Croatica, vol.47, no. Supplement 1, pp. 63-66, 2008. [Online]. Available: https://hrcak.srce.hr/index.php/22769. [Accessed: 05 January 2025]
Abstract
The aim of this study was to evaluate early treatment response following intravitreal bevacizumab therapy in 4 patients with neovascular glaucoma. Four patients with neovascular glaucoma and pronounced congestion of anterior chamber received intravitreal bevacizumab injection (1.25 mg/0.05 mL). Intravitreal bevacizumab resulted in marked regression of anterior segment neovascularization documented by fluorescein angiography and iridography, and relief of symptoms within 24 hours. Cyclocryocoagulation was carried out only if pressure was insufficiently controlled by topical therapy. Follow up examination was performed at 1 month. In conclusion, intravitreal bevacizumab leads to rapid regression of iris and angle neovacularization in the early period of observation. Controlled randomized trial is needed to test whether intraocular injections of bevacizumab provide long term benefit to patients with neovascular glaucoma.
Keywords
Neovascular glaucoma; Bevacizumab
Hrčak ID:
22769
URI
https://hrcak.srce.hr/22769
Publication date:
1.4.2008.
Article data in other languages:
croatian
Visits: 2.116
*
